Qiagen to Spend $1.6B to Acquire Digene; Eyes Cancer, Women's Health MDx Market

The acquisition will enable Qiagen to branch out beyond its current diagnostics focus on infectious diseases and into cancer testing, and will provide Digene with a global sales channel that it currently lacks.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.